M V Hospital for Diabetes [P] Limited
Chennai, Tamil Nadu, 600013, India
NCT Number: NCT05721092
Asia has the highest burden with the largest contribution of pneumonia burden from India. Pneumonia is also observed as 5th leading cause of deaths in India. People with diabetes with uncontrolled glucose are significantly at higher risk of development of pneumonia. Even though, pneumonia is a vaccine-preventable disease, hospitalization for pneumonia of patients with diabetes are rising. Very limited literature is available on the knowledge and practice of pneumonia vaccination among diabetologists and the rate of pneumonia vaccination received by the patients with diabetes. Hence this study aims to assess their knowledge on the same. In addition, this study also aims to identify the real barriers and facilitators of pneumococcal vaccination among diabetologists in India. A cross-sectional study will be conducted among 25diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
Looking for future studies?
Notify Me25 year–65 year
All sexes
Observational
Chennai, Tamil Nadu, 600013, India
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diabetologists willing to participate in the study
Exclusion criteria
Unwillingness to give consent for participation
A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
M.V. Hospital for Diabetes
Other
Assessment of Knowledge, Facilitators and Barriers of Pneumococcal Vaccination: A Cross-sectional Study Among Diabetologists in India
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03098628
Pneumococcal Vaccine
Ho Chi Minh City, Vietnam
View Trial DetailsNCT05788510
Pneumococcal Vaccine
Pontoise, France
View Trial DetailsNCT01521897
Pneumococcal Vaccine, Streptococcus Pneumoniae
Kasuga, Fukuoka, Japan
View Trial DetailsNCT00689351
Disease, Pathologic Processes
Incheon, Bupyeong-gu, South Korea
View Trial Details